Marcely Gimenes Bonatto

Marcely Gimenes Bonatto

Auto-generated profile, based on publicly available information

Marcely Gimenes Bonatto

Hospital Santa Casa de Misericórdia de Curitiba, Curitiba, PR - Brasil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2021 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
FMFabiana Marcondes-Braga
Fabiana Marcondes-Braga
LMLídia Ana Zytynski Moura
Lídia Ana Zytynski Moura
VIVictor Sarli Issa
Victor Sarli Issa
JVJefferson Luis Vieira
Jefferson Luis Vieira
LRLuis Eduardo Rohde
Luis Eduardo Rohde
EMEvandro Tinoco Mesquita
Evandro Tinoco Mesquita
Introdução A última Diretriz de Insuficiência Cardíaca do Departamento de Insuficiência Cardíaca da Sociedade Brasileira de Cardiologia (DEIC/SBC) foi finalizada em março de 2018. A partir de então, houve um importante número de intervenções terapêuticas e abordagens diagnósticas que surgiram ou se consolidaram na prática clínica internacional e na pesquisa clínica. Ao lado disso, a pandemia da COVID-19 trouxe-nos conhecimento sobre o modelo fisiopatológico da agressão miocárdica e muitas dúvidas acerca da continuidade e da segurança dos medicamentos nos pacientes [...] Introdução A última Diretriz de Insuficiência Cardíaca do Departamento de Insuficiência Cardíaca da Sociedade Brasileira de Cardiologia (DEIC/SBC) foi finalizada em março de 2018. A partir de então, houve um importante número de intervenções terapêuticas e abordagens diagnósticas que surgiram ou se consolidaram na prática clínica internacional e na pesquisa clínica. Ao lado disso, a pandemia da COVID-19 trouxe-nos conhecimento sobre o modelo fisiopatológico da agressão miocárdica e muitas dúvidas acerca da continuidade e da segurança dos medicamentos nos pacientes

31 August 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
LGLivia Adams Goldraich
Livia Adams Goldraich
Santiago Alonso Tobar LeitãoSantiago Alonso Tobar Leitão
Santiago Alonso Tobar Leitão
FSFernando Luis Scolari
Fernando Luis Scolari
FMFabiana Marcondes-Braga
Fabiana Marcondes-Braga
MBMarcely Gimenes Bonatto
Marcely Gimenes Bonatto
NCNadine Clausell
Nadine Clausell
: Heart transplantation is the standard of therapy for patients with end-stage heart disease. Since the first human-to-human heart transplantation, performed in 1967, advances in organ donation, surgical techniques, organ preservation, perioperative care, immunologic risk assessment, immunosuppression agents, monitoring of graft function and surveillance of long-term complications have drastically increased recipient survival. However, there are yet many challenges in the modern era of heart transplantation in which immunosuppression may play a key role in further advances in the field. A fine-tuning of immune modulation to prevent graft rejection while avoiding side effects from over immunosuppression has been the vital goal of basic and clinical research. Individualization of drug choices and strategies, taking into account the recipient's clinical characteristics, underlying heart failure diagnosis, immunologic risk and comorbidities seem to be the ideal approaches to improve post-transplant morbidity and survival while preventing both rejection and complications of immunosuppression. : The aim of the present review is to provide a practical, comprehensive overview of contemporary immunosuppression in heart transplantation. Clinical evidence for immunosuppressive drugs is reviewed and practical approaches are provided. Cardiac allograft rejection classification and up-to-date management are summarized. Expanding therapies, such as photophoresis, are outlined. Drug-to-drug interactions of immunosuppressive agents focused on cardiovascular medications are summarized. Special situations involving heart transplantation such as sarcoidosis, Chagas diseases and pediatric immunosuppression are also reviewed. The evolution of phamacogenomics to individualize immunosuppressive therapy is described. Finally, future perspectives in the field of immunosuppression in heart transplantation are highlighted.

10 April 2024 in Current Medical Research and Opinion
Verified
Journal Article
Open access
MOMucio Tavares de Oliveira
Mucio Tavares de Oliveira
RBRui Baptista
Rui Baptista
SCSergio A. Chavez-Leal
Sergio A. Chavez-Leal
MBMarcely Gimenes Bonatto
Marcely Gimenes Bonatto
Heart failure (HF) is associated with disabling symptoms, poor quality of life, and a poor prognosis with substantial excess mortality in the years following diagnosis. Overactivation of the sympathetic nervous system is a key feature of the pathophysiology of HF and is an important driver of the process of adverse remodelling of the left ventricular wall that contributes to cardiac failure. Drugs which suppress the activity of the renin-angiotensin-aldosterone system, including β-blockers, are foundation therapies for the management of heart failure with reduced ejection fraction (HFrEF) and despite a lack of specific outcomes trials, are also widely used by cardiologist in patients with HF with preserved ejection fraction (HFpEF). Today, expert opinion has moved away from recommending that treatment for HF should be guided solely by the LVEF and interventions should rather address signs and symptoms of HF (e.g. oedema and tachycardia), the severity of HF, and concomitant conditions. β-blockers improve HF symptoms and functional status in HF and these agents have demonstrated improved survival, as well as a reduced risk of other important clinical outcomes such as hospitalisation for heart failure, in randomised, placebo-controlled outcomes trials. In HFpEF, β-blockers are anti-ischemic and lower blood pressure and heart rate. Moreover, β-blockers also reduce mortality in the setting of HF occurring alongside common comorbid conditions, such as diabetes, CKD (of any severity), and COPD. Higher doses of β-blockers are associated with better clinical outcomes in populations with HF, so that ensuring adequate titration of therapy to their maximal (or maximally tolerated) doses is important for ensuring optimal outcomes for people with HF. In principle, a patient with HF could have combined treatment with a β-blocker, renin-angiotensin-aldosterone system inhibitor/neprilysin inhibitor, mineralocorticoid receptor antagonist, and a SGLT2 inhibitor, according to tolerability.

12 April 2022 in ABC Heart Failure & Cardiomyopathy
Verified
Journal Article
Closed access
PDF file
MBMarcely Gimenes Bonatto
Marcely Gimenes Bonatto
ACAndressa de Oliveira Coiradas
Andressa de Oliveira Coiradas
LMLídia Ana Zytynski Moura
Lídia Ana Zytynski Moura
Pharmacological treatment of heart failure with reduced ejection fraction (HFREF) has undergone changes over the years as discoveries have been made related to new systems involved in its pathophysiology and, consequently, of new therapeutic targets. For this treatment, certain drug classes have become essential and should be used in combinations with the objective of reducing the disease’s high rates of morbidity and mortality. They are therefore considered the pillars of treatment for patients with HFREF. These drug classes act [...] Abstract Pharmacological treatment of heart failure with reduced ejection fraction (HFREF) has undergone changes over the years as discoveries have been made related to new systems involved in its pathophysiology and, consequently, of new therapeutic targets. For this treatment, certain drug classes have become essential and should be used in combinations with the objective of reducing the disease’s high rates of morbidity and mortality. They are therefore considered the pillars of treatment for patients with HFREF. These drug classes act

29 June 2022 in ABC Heart Failure & Cardiomyopathy
Verified
Journal Article
Closed access
PDF file
VKVitoria A. A. Koga
Vitoria A. A. Koga
LDLuiza Dall’aSta
Luiza Dall’aSta
TJThiago L. P. Jacyntho
Thiago L. P. Jacyntho
LDLeonardo C. De-Marchi
Leonardo C. De-Marchi
RMRodrigo P. Mulinari
Rodrigo P. Mulinari
MFMiguel Morita Fernandes-Silva
Miguel Morita Fernandes-Silva
Background: The adherence to guideline-directed medical therapy in patients with heart failure (HF) remains suboptimal. Objectives: We evaluated the association between age and adherence to guideline-directed medical therapy in patients with chronic HF and explored whether polypharmacy and comorbidities might explain this association. Methods: We performed a cross-sectional study of 374 patients with chronic HF and left ventricle ejection fraction < 50% (23 to 89 years old, 33% women) between 2018 and 2019. GDMT was defined as using HF-related [...] Abstract Background: The adherence to guideline-directed medical therapy in patients with heart failure (HF) remains suboptimal. Objectives: We evaluated the association between age and adherence to guideline-directed medical therapy in patients with chronic HF and explored whether polypharmacy and comorbidities might explain this association. Methods: We performed a cross-sectional study of 374 patients with chronic HF and left ventricle ejection fraction < 50% (23 to 89 years old, 33% women) between 2018 and 2019. GDMT was defined as using HF-related

31 December 2023 in ABC Heart Failure & Cardiomyopathy
Verified
Journal Article
Open access
PDF file
MBMarcely Gimenes Bonatto
Marcely Gimenes Bonatto
ACAndressa de Oliveira Coiradas
Andressa de Oliveira Coiradas
LMLuana Monferdini
Luana Monferdini
AFAna Karyn Ehrenfried de Freitas
Ana Karyn Ehrenfried de Freitas
Nearly 80% of all patients hospitalized for decompensated heart failure (HF) present hypervolemia with signs and symptoms of congestion,, for which decongestion is an essential pillar of treatment. Most guidelines recommend the use of loop diuretics as soon as the patient is admitted.– Despite this, a post-hoc analysis of the DOSE-AHF and CARRESS-HF studies showed that only half of these patients were free of congestion at the moment of high discharge, this being the group with the highest mortality [...] Abstract Nearly 80% of all patients hospitalized for decompensated heart failure (HF) present hypervolemia with signs and symptoms of congestion,, for which decongestion is an essential pillar of treatment. Most guidelines recommend the use of loop diuretics as soon as the patient is admitted.– Despite this, a post-hoc analysis of the DOSE-AHF and CARRESS-HF studies showed that only half of these patients were free of congestion at the moment of high discharge, this being the group with the highest mortality